trial

Pregnenolone in the Management of Schizophrenia Patients

NCTId NCT00174889
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 60
Sponsored by Sha'ar Menashe Mental Health Center
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
60
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2005-01
Primary completion
—
Eligibility
ALL · 20 Years · 55 Years

Interventions & indications

Drugs
Pregnenolone

Sponsors

Sha'ar Menashe Mental Health CenterLead Sponsor
Beersheva Mental Health CenterCollaborator

Investigators

1
Michael S. Ritsner, MD, PhDPrincipal Investigator

Sites

1 total
Hadera, Israel

Facts & assertions

3 sourced
Enrollment
60
Phase
PHASE1
Status
COMPLETED
relationships
The graph out of here
drug
Pregnenolone
drug
lead_sponsor
Sha'ar Menashe Mental Health Center
company
collaborator
Beersheva Mental Health Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Michael S. Ritsner, MD, PhD
person